阿托伐他汀治疗慢性肺源性心脏病性肺动脉高压的临床研究  

Cilinical study of atorvastatin on pulmonary hypertension with chronic pulmonary heart disease

作　　者：曹维锷[1] 王伟[1] 曹佳齐[1] 马欣[1] 顾水明[1] 

机构地区：[1]上海市徐汇区中心医院,上海200031

出　　处：《现代中西医结合杂志》2011年第26期3261-3263,共3页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的观察阿托伐他汀治疗慢性肺源性心脏病性肺动脉高压的临床疗效及对高敏C反应蛋白(hs-CRP)的影响。方法 50例慢性肺源性心脏病性肺动脉高压患者随机分为治疗组25例、对照组25例。治疗组采用基础治疗+阿托伐他汀治疗,对照组采用基础治疗+地尔硫治疗,2组治疗前、治疗6周后行血气分析测定,观察治疗后呼吸困难症状改善的有效率和肺动脉压及hs-CRP的测定。结果治疗后,2组较治疗前p(O2)均明显提高,p(CO2)明显降低(P均<0.01),但2组治疗后无显著性差异(P>0.05)。治疗组呼吸困难症状改善有效率(68%)高于对照组(36%),有显著性差异(P<0.01)。2组平均肺动脉压和hs-CRP治疗后较治疗前均明显降低(P<0.01或0.05),治疗组较对照组改善更为明显(P<0.01或0.05)。结论阿托伐他汀能有效降低慢性肺源性心脏病性肺动脉高压,并使hs-CRP含量下降,阿托伐他汀降低肺动脉高压可能与抑制肺血管炎性反应有关。Objective It is to observe the clinical curative effect of atorvastatin on pulmonary hypertension with chronic pulmonary heart disease and the influence on high sensitive C reaction protein（hs-CRP）.Methods Fifty patients with pulmonary hypertension with chronic pulmonary heart disease were randomly divided into two groups.Twenty-five cases were in treatment group and treated with routine treatment and atorvastatin.The other 25 cases were in control group and treated with routine treatment and diltiazem.The two groups were determined blood gas analysis before treatment and after treatment for 6 weeks.The effective rate of dyspnea improving after treatment was observed.The change of pulmonary arterial pressure（PAPs） and the level of hs-CRP were detected.Results Compared with before treatment,the p（O2） in both groups after treatment obviously heightened and the p（CO2） obviously lowered（both P0.01）,but the differences between two groups after treatment were not significant（P0.05）.The effective rate of dyspnea improving in treatment group（68%） was higher than that in control group（36%） and the difference was significant（P0.01）.The PAPs and the level of hs-CRP in the two groups after treatment were obviously lower than those before treatment（P0.01 or 0.05）,and the improvements of treatment group were more significant than that of control group（P0.01 or 0.05）.Conclusion Atorvastatin can effectively lower pulmonary hypertension with chronic pulmonary heart disease and the level of hs-CRP.The effect may be related to inhibiting the inflammation of pneumal blood vessels.

关 键 词：阿托伐他汀 慢性肺源性心脏病 肺动脉高压 高敏C反应蛋白 

分 类 号：R541.5[医药卫生—心血管疾病]